The current king versus the triple-agonist that might dethrone it. One's approved, one's not.
Bottom line: On raw efficacy numbers, retatrutide blows semaglutide out of the water — nearly double the weight loss. But retatrutide is not approved, not available, and has only Phase 2 data. Semaglutide is the proven, available, Tier 1 option today. This comparison is really about 'what exists' vs 'what's coming,' and no one should wait for retatrutide when semaglutide works right now.
| Semaglutide | Retatrutide | |
|---|---|---|
| Category | GLP-1 receptor agonist | Triple agonist (GLP-1/GIP/glucagon) |
| Mechanism | Activates GLP-1 receptors — suppresses appetite, slows gastric emptying | Hits three receptors simultaneously — appetite suppression plus glucagon-driven fat metabolism and liver fat reduction |
| Reported dose | 0.25–2.4 mg weekly (injection) | 1–12 mg weekly (Phase 2 trial doses) |
| Frequency | Once weekly | Once weekly |
| Weight loss (trials) | ~14.9% at 68 weeks (STEP 1, 2.4 mg) | ~24.2% at 48 weeks, up to 28.7% at 68 weeks (Phase 2, highest dose) |
| Top side effect | Nausea, vomiting, diarrhea during dose titration | Nausea, diarrhea, vomiting — similar GI profile but higher rates at top doses |
| Evidence tier | Tier 1 — extensive Phase 3 data, approved and widely prescribed | Tier 3 — Phase 2 completed, Phase 3 ongoing, no approval yet |
| Common vial size | 5 mg or 10 mg vials (compounded) | Not commercially available — research/trial supply only |
| Approval status | FDA-approved (Ozempic, Wegovy) | Investigational — Eli Lilly Phase 3 trials in progress, no approval date announced |
Semaglutide is the rational choice right now because you can actually get it. It has years of real-world safety data, multiple approved formulations, and a well-understood side effect profile. If you need to start weight loss treatment today, this is the one.
Retatrutide is for the 'what's coming next' conversation. The Phase 2 data showing nearly 29% weight loss at 68 weeks is legitimately unprecedented. If it survives Phase 3 and gets approved, the glucagon receptor activation could make it the most powerful obesity drug ever made. But you cannot get it yet through any legitimate channel.
On raw efficacy numbers, retatrutide blows semaglutide out of the water — nearly double the weight loss. But retatrutide is not approved, not available, and has only Phase 2 data. Semaglutide is the proven, available, Tier 1 option today. This comparison is really about 'what exists' vs 'what's coming,' and no one should wait for retatrutide when semaglutide works right now.
← Browse all peptides | All comparisons →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify